Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1741
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV